BRA
SMMT icon

Bender Robert & Associates’s Summit Therapeutics SMMT Stock Holding History

Bender Robert & Associates’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-14,059
Closed -$110K – 77
2024
Q2 		$110K Buy
+14,059
New +$75.9K 0.02% 41

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Bender Robert & Associates's SMMT Position: Q1 2025 in Review

Bender Robert & Associates sold out of Summit Therapeutics (SMMT) in Q1 2025, closing a stake of 11,496 shares — an estimated $205K sold.

Bender Robert & Associates first reported a position in SMMT in Q1 2021 and held it in 8 quarters. The position peaked at $205K in Q4 2024. 212 funds tracked by Wall St. Rank hold SMMT as of Q1 2025.

  • Bender Robert & Associates reported no remaining Summit Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Bender Robert & Associates sold 11,496 Summit Therapeutics shares in Q1 2025, an estimated $205K.
  • Bender Robert & Associates first reported a position in Summit Therapeutics in Q1 2021 and held it in 8 quarters.
  • Bender Robert & Associates's Summit Therapeutics position peaked at $205K in Q4 2024.
  • 212 funds tracked by Wall St. Rank held Summit Therapeutics as of Q1 2025.

Based on Bender Robert & Associates's 13F filing for Q1 2025, filed 18 Apr 2025.